Actualités

The company still has a strong lead in its core therapeutic area.

Novo Nordisk's oral semaglutide for obesity is gaining traction as demand picks up for the new pill version of Ozempic. The FDA has proposed restricting compounding of GLP-1 drugs such as semaglutide, which could support branded products. Rival Eli Lilly is facing delays to its own obesity pill, giving Novo Nordisk more room to build its lead in oral GLP-1 therapies. Novo Nordisk is responding with new leadership, pricing changes, and cost reductions to sharpen its obesity drug focus. Novo...

Eli Lilly and Company (NYSE:LLY) held its 2026 annual meeting of shareholders virtually, with Vice President of Sustainability Jim Greffet moderating and Chair, President, and CEO Dave Ricks leading the formal business and post-vote remarks. Greffet opened the meeting with standard notices about for

Eli Lilly's valuation looks far more attractive now than it did even a year ago.

These stocks have been struggling over the past year, but their growth days are far from over.

The hosts of Morning Brew Daily made a simple argument on a recent episode that the idea of the “Ozempic economy” should be replaced with the “Mounjaro economy” now that Eli Lilly is controlling 60% of the GLP-1 market. Lilly’s Q1 2026 earnings report backs that up. Lilly’s Dominance, by the Numbers Eli Lilly (NYSE:LLY) ... Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Eli Lilly (NYSE:LLY) just delivered one of the strongest first quarters in big pharma history, but shares have pulled back sharply from their February peak. That gap between operating performance and stock price is where our model sees opportunity. Our 24/7 Wall St. price target for Eli Lilly is $1,133.12 over the next 12 months, ... Our Strongest Conviction Call: Eli Lilly Headed 21% Higher in 12 Months

Eli Lilly is coming off an impressive first-quarter performance, with sales soaring by 56%.

If you are wondering whether Eli Lilly's current share price still makes sense after a strong multi year run, the next sections will help you frame what you might actually be paying for. The stock last closed at US$963.33, with returns of 10.9% over the past week, 3.0% over the past month, a 10.8% year to date decline, 18.1% over the last year and a very large gain over five years. Recent coverage has focused on Eli Lilly's expanding role in treatments for chronic conditions and the scale of...

Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street H

ABBV jumps 5% after a Q1 beat and higher 2026 guidance, but Skyrizi, Rinvoq and a deep pipeline may matter more for its post-earnings outlook

Fresh Safety Concerns Hit Eli Lilly as FDA Reviews Drug Case

Liver failure report raises early questions post launch

We recently published Jim Cramer Commented On Big Market Confusion & Discussed These 20 Stocks. Eli Lilly and Company (NYSE:LLY) is one of the stocks discussed by Jim Cramer. Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is one of Cramer’s favorite stocks in the space. The shares are up by 16.9% over the past year […]

NVO heads into Q1 with strong GLP-1 drug demand and new Wegovy pill rollout, but pricing pressure, weak guidance and Eli Lilly rivalry weigh on outlook.

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and reflects a model update rather than a wholesale thesis change. Amgen stock recently slipped, trading at $324 as of Monday after closing at ... Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?

ANI Pharmaceuticals, Novavax and three other biotechs show strong Earnings ESP signals, hinting at potential Q1 earnings beat as sector results roll in.

The Food and Drug Administration has recorded two ‘serious’ cases in patients taking Eli Lilly’s weight-loss pill.

May 4 (Reuters) - Global drugmakers have been ramping up U.S. manufacturing and stockpiling inventory as the Trump administration moves to impose 100% tariffs on branded drugs unless companies cut

Eli Lilly stock toppled Monday after a patient taking its new weight-loss pill, Foundayo, experienced liver failure.

I keep buying Eli Lilly (NYSE:LLY), and the latest quarter just made it harder to stop. This is a confession of conviction. I have been adding through every dip in 2026, and the most recent earnings report told me the thesis is accelerating. What pulls me back to the buy button is simple. Lilly sits ... This Pharma Stock Keeps Earning My Money, Here’s Why

Investing.com -- Eli Lilly and Company (NYSE:LLY) fell 3% Monday, while Novo Nordisk (NYSE:NVO) rose 2% after Evercore ISI analyst Umer Raffat flagged a liver case in the FDA adverse event database that has "potential to create confusion" for Eli Lilly.

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Over the last 7 days, the United States market has remained flat, although it has experienced a notable 28% increase over the past year and earnings are forecast to grow by 16% annually. In this context of overall growth, identifying stocks that may be trading below their fair value can offer opportunities for investors seeking to capitalize on potential undervaluation in the market.

Lilly's weight loss drugs have been delivering blockbuster revenue.

A new weight loss pill is expanding the pharmaceutical leader's already massive market opportunity.

Is NVO a good stock to buy? We came across a bullish thesis on Novo Nordisk A/S on Unfair Advantage’s Substack by AK. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S’s share was trading at $38.52 as of April 23rd. NVO’s trailing and forward P/E were 10.65 and 11.38 respectively according […]

Eli Lilly and Company (NYSE:LLY) was among the stocks Jim Cramer highlighted, as he discussed the massive AI infrastructure buildout. Cramer noted that the company is “creating a lot of jobs,” as he said: Okay, then there’s one that’s totally away from manufacturing or industry or tech, and that’s Eli Lilly. It was up 10%. […]

Eli Lilly and Company ( NYSE:LLY ) investors will be delighted, with the company turning in some strong numbers with...

Growth investors picking a large-cap vehicle in 2026 face a real choice: pay nothing for a passive index, or pay a few basis points for an active manager who claims to add value. The Fidelity Enhanced Large Cap Growth ETF (NYSEARCA:FELG) sits squarely in that second camp, charging 0.18% for an actively managed take on ... Why Growth Investors Are Ditching FELG for the NASDAQ-100’s 9.74% Edge